The global viral vector vaccines market has exhibited impressive growth reaching a market size of US$ 780 million at the close of 2024, according to a recent study. The market is poised for continued expansion, reaching a market valuation of US$ 1100 million by 2031.
The Ebola virus, notorious for causing severe and often fatal Ebola virus disease (EVD), has been a subject of intense vaccine development efforts. Viral vector vaccines have emerged as a promising approach in combating Ebola, leading to significant market growth. Factors contributing to this expansion include the rising incidence of EVD globally, increased investments by both governments and private sectors in Ebola vaccine research and production.
United States: The U.S. government's substantial funding and support for Ebola viral vector vaccine development have propelled market growth. The nation's focus on public health preparedness has also increased the demand for effective Ebola vaccines.
South Africa: Research and development activities focused on the development of viral vector vaccines against Ebola have intensified in South Africa. Collaborations between pharmaceutical companies and research institutions are expected to accelerate vaccine development and drive market growth.
This product will be delivered within 1-3 business days.
Revolutionizing Vaccine Delivery with Viral Vectors
Viral vector vaccines play a pivotal role in delivering genetic material or DNA via vaccines. This genetic material is transcribed by the host cells, eliciting an immune response. Currently, only six viral vector vaccines have received approval from the United States FDA for use in humans, comprising two Ebola vaccines and four COVID-19 vaccines.The Ebola virus, notorious for causing severe and often fatal Ebola virus disease (EVD), has been a subject of intense vaccine development efforts. Viral vector vaccines have emerged as a promising approach in combating Ebola, leading to significant market growth. Factors contributing to this expansion include the rising incidence of EVD globally, increased investments by both governments and private sectors in Ebola vaccine research and production.
Demand Drivers for Viral Vector Vaccines
- Escalating Infectious Diseases: The increasing prevalence of infectious diseases such as Ebola, Zika, and HIV necessitates more effective vaccines, driving the demand for viral vector vaccines. The emergence of pandemic-level diseases has led to greater vaccine procurement by international organizations like UNICEF.
- UNICEF Initiatives: UNICEF is actively collaborating with national governments to ensure timely access to affordable, high-quality vaccines. Several initiatives are underway to strengthen vaccine procurement worldwide, contributing to the growth of the viral vector vaccines market.
- Global Ebola Vaccine Security Plan: To meet the demand for Ebola vaccines and enhance vaccine security, organizations like WHO are partnering with entities like the Global Alliance for Vaccine and Immunization (GAVI) and UNICEF. This includes increasing vaccine supply capacity and the number of manufacturers.
Challenges to Adoption
- High Development Costs: The vaccine development process is intricate, costly, and time-consuming, requiring collaboration among scientists, healthcare professionals, industry players, and society. The expenses involved in vaccine development range from US$ 700 million to US$ 1 billion.
- Vaccination Hesitancy: Challenges such as vaccination hesitancy, stringent safety regulations, varying efficacy demands, and a limited number of vaccine manufacturers can hinder market growth.
Country-wise Insights
North Africa: Recent Ebola outbreaks in West and Central Africa have spurred awareness and demand for Ebola vaccinations in North Africa. Governments in the region are investing in vaccination programs to prevent the spread of infectious diseases, furthering market growth.United States: The U.S. government's substantial funding and support for Ebola viral vector vaccine development have propelled market growth. The nation's focus on public health preparedness has also increased the demand for effective Ebola vaccines.
South Africa: Research and development activities focused on the development of viral vector vaccines against Ebola have intensified in South Africa. Collaborations between pharmaceutical companies and research institutions are expected to accelerate vaccine development and drive market growth.
Competitive Landscape
Leading pharmaceutical companies are actively pursuing mergers, acquisitions, and regional development to bolster their market presence and diversify their product portfolios.Key Companies in the Market:
- Merck & Co., Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
Key Segments of Viral Vector Vaccines Industry Research
Patient:
- Pediatric
- Adults
Distribution Channel:
- Hospitals
- Government Institutes
Region:
- North America
- Europe
- East Asia
- Middle East & Africa
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Market Overview
3. Global Viral Vector Vaccines Market Outlook, 2018 - 2031
4. North America Viral Vector Vaccines Market Outlook, 2018 - 2031
5. Europe Viral Vector Vaccines Market Outlook, 2018 - 2031
6. Asia Pacific Viral Vector Vaccines Market Outlook, 2018 - 2031
7. Latin America Viral Vector Vaccines Market Outlook, 2018 - 2031
8. Middle East & Africa Viral Vector Vaccines Market Outlook, 2018 - 2031
9. Competitive Landscape
10. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck & Co., Inc.
- Johnson & Johnson ( Janssen Global Services, LLC)
Methodology
LOADING...
